Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTUNASDAQ:BOLTNASDAQ:MRKRNASDAQ:ONCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$1.96-3.0%$1.28$0.95▼$3.24$12.09M-0.1321,882 shs223,842 shsBOLTBolt Biotherapeutics$0.32-0.9%$0.36$0.29▼$0.81$12.35M0.96194,068 shs225,820 shsMRKRMarker Therapeutics$1.14+0.9%$1.16$0.95▼$5.99$12.90M1.2962,936 shs16,542 shsONCROncorus$0.13$0.07$0.01▼$0.47$3.29M3.61.33 million shs135,947 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma-2.97%-7.98%+84.91%+45.19%-37.18%BOLTBolt Biotherapeutics-0.92%+9.90%-13.44%-34.02%-57.91%MRKRMarker Therapeutics+0.88%+2.70%-2.56%-27.39%-71.07%ONCROncorus0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYTUAytu BioPharma1.4544 of 5 stars0.03.00.03.42.71.70.6BOLTBolt Biotherapeutics3.234 of 5 stars3.25.00.00.03.11.71.3MRKRMarker Therapeutics4.2139 of 5 stars3.85.00.03.91.90.80.6ONCROncorusN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYTUAytu BioPharma 0.00N/AN/AN/ABOLTBolt Biotherapeutics 2.33Hold$2.50676.40% UpsideMRKRMarker Therapeutics 3.50Strong Buy$13.171,054.97% UpsideONCROncorus 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONCR, MRKR, BOLT, and AYTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/13/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.25 ➝ $1.004/1/2025MRKRMarker TherapeuticsWBB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$12.50 ➝ $12.503/25/2025BOLTBolt BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/25/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.50 ➝ $1.253/5/2025MRKRMarker TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$81.66M0.15N/AN/A$4.64 per share0.42BOLTBolt Biotherapeutics$3.64M3.39N/AN/A$2.97 per share0.11MRKRMarker Therapeutics$6.59M1.96N/AN/A$1.58 per share0.72ONCROncorusN/AN/AN/AN/A$2.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A-7.62%-19.30%-4.80%N/ABOLTBolt Biotherapeutics-$69.20M-$1.67N/AN/AN/A-665.56%-69.46%-48.55%8/12/2025 (Estimated)MRKRMarker Therapeutics-$8.24M-$1.33N/AN/AN/A-179.74%-89.63%-71.62%N/AONCROncorus-$77.42M-$3.49N/A∞N/AN/AN/AN/AN/ALatest ONCR, MRKR, BOLT, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025AYTUAytu BioPharma-$0.17$0.20+$0.37$0.21$13.74 million$18.45 million5/12/2025Q1 2025BOLTBolt Biotherapeutics-$0.34-$0.29+$0.05-$0.29$0.77 million$1.22 million3/31/2025Q4 2024MRKRMarker Therapeutics-$0.28-$0.42-$0.14-$0.42$5.25 million$1.22 million3/24/2025Q4 2024BOLTBolt Biotherapeutics-$0.38-$0.38N/A-$0.42$0.79 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/ABOLTBolt Biotherapeutics$0.36111.80%N/AN/A N/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/AONCROncorusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.320.980.81BOLTBolt Biotherapeutics0.213.163.16MRKRMarker TherapeuticsN/A3.153.15ONCROncorusN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%BOLTBolt Biotherapeutics86.70%MRKRMarker Therapeutics22.39%ONCROncorus20.07%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma3.60%BOLTBolt Biotherapeutics6.10%MRKRMarker Therapeutics14.50%ONCROncorus17.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma1606.17 million6.00 millionNot OptionableBOLTBolt Biotherapeutics9038.34 million26.45 millionNot OptionableMRKRMarker Therapeutics6011.32 million9.16 millionNot OptionableONCROncorus6426.09 million21.63 millionOptionableONCR, MRKR, BOLT, and AYTU HeadlinesRecent News About These CompaniesRFL Rafael Holdings, Inc.August 1, 2024 | seekingalpha.comOncorus Inc rdinary Shares Stock (OTC:ONCR) Dividends: History, Yield and DatesFebruary 26, 2024 | benzinga.comOncorus, Inc. (ONCR) stock price, news, quote & history – Yahoo FinanceDecember 29, 2023 | uk.finance.yahoo.comComera Life Sciences Holdings IncDecember 18, 2023 | investing.comOncorus Inc Ordinary SharesOctober 28, 2023 | morningstar.comONCR Historical DataOctober 16, 2023 | investing.comOncorus Inc. (ONCR) receives a Buy rating from Maxim GroupJune 21, 2023 | knoxdaily.comTaking a look at what insiders are doing to gauge the Oncorus Inc. (ONCR)’s directionJune 16, 2023 | knoxdaily.comWhat's Going On With Oncorus (ONCR) Stock Friday?June 16, 2023 | msn.comMaxim Group gives a Buy recommendation for Oncorus Inc. (ONCR)June 15, 2023 | knoxdaily.comONCR price target predicted to rise nearly $1.50 in 12 monthsJune 9, 2023 | knoxdaily.comOncorus could file for bankruptcy as most employees laid off; down 43%June 2, 2023 | msn.comDays-to-cover ratio for ONCR declines to 2.51 due to decline in short interestJune 1, 2023 | knoxdaily.comOncorus Announces Workforce Reduction PlanJune 1, 2023 | finance.yahoo.comOncorus, Inc.: Oncorus Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 23, 2023 | finanznachrichten.deRecap: Oncorus Q1 EarningsMay 22, 2023 | msn.comOncorus Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 22, 2023 | finance.yahoo.comOncorus, Inc.: Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 24, 2023 | finanznachrichten.deOncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 24, 2023 | finance.yahoo.comFor some biotechs moving on from SVB, not all traditional banks are an optionMarch 15, 2023 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCR, MRKR, BOLT, and AYTU Company DescriptionsAytu BioPharma NASDAQ:AYTU$1.96 -0.06 (-2.97%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.98 +0.02 (+0.77%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Bolt Biotherapeutics NASDAQ:BOLT$0.32 0.00 (-0.92%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.31 -0.01 (-2.80%) As of 05/23/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Marker Therapeutics NASDAQ:MRKR$1.14 +0.01 (+0.88%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.10 -0.03 (-3.07%) As of 05/23/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Oncorus NASDAQ:ONCROncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
